← Leaderboards
Raj Advani
Stanford University
$203,749
Attributed
$203,749
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $119.4K · FY2005–08$200K$150K$100K$50K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$203,749 · 11
By mechanism
M01$203,749 · 11
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Katherine W Ferrara$45,937,231
- Josquin Foiret$1,049,885
- Joachim F Hallmayer$22,996,573
- Booil Jo$4,144,125
- A. Dimitrios Colevas$5,652,313
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyGrantResourcesUnited States National Institutes Of HealthInstitutionSourceComputer Retrieval Of Information On Scientific Projects DatabaseFundingResearch PersonnelRelapseRateLymphoma, Non-Hodgkin&AposClinical TrialsIn Complete RemissionStable DiseaseResponseRefractoryDesignDosePartial ResponseProgressive DiseaseClinical Trials, Phase IiB-LymphocytesIndolent
Grant awards (11)
CLINICAL TRIAL: SGN-40 (ANTI-HUCD40 MAB) IN RELAPSED DIFFUSE LARGE B-CELL LYMPHO$14,449
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PXD101 IN RECURRENT OR REFRACTORY CUTANEOUS AND PERIPHERAL T-CEL$3,527
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SGN-40 (ANTI-HUCD40 MAB) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA$796
M01 · FY2008 · RR · contact PI
SGN-40 (ANTI-HUCD40 MAB) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA$93,623
M01 · FY2007 · RR · contact PI
PXD101 IN PATIENTS WITH RECURRENT OR REFRACTORY CUTANEOUS AND PERIPHERAL T-CELL$15,214
M01 · FY2007 · RR · contact PI
TRIAL OF MOTEXAFIN GADOLINIUM (MGD) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA$10,533
M01 · FY2007 · RR · contact PI
STUDY OF SGN-40 (ANTI-HUCD40 MAB) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA$32,468
M01 · FY2006 · RR · contact PI
VELCADE IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA$16,012
M01 · FY2006 · RR · contact PI
TRIAL OF MOTEXAFIN GADOLINIUM (MGD) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA$15,122
M01 · FY2006 · RR · contact PI
TRIAL OF MOTEXAFIN GADOLINIUM (MGD) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA$1,671
M01 · FY2005 · RR
VELCADE IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA$334
M01 · FY2005 · RR